Reversible nonthrombocytopenic palpable purpura associated with metoclopramide

Annals of Pharmacotherapy

Volumn 33, Issue 1, 1999, Pages 35-37

  Goad, Jeffery A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Metoclopramide; Nonthrombocytopenic palpable purpura

Indexed keywords

METOCLOPRAMIDE; PROCAINAMIDE;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PURPURA; THROMBOCYTE COUNT;

ABDOMINAL PAIN; AGED; DIABETES MELLITUS, TYPE 1; HUMANS; MALE; MEDLINE; METOCLOPRAMIDE; PURPURA, SCHOENLEIN-HENOCH;

EID: 0032955392     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18058     Document Type: Article

References (8)

1. Package insert. Metoclopramide. Dayton, NJ: Invamed, Inc., 1994.
2. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Metoclopramide: a review of its pharmacological properties and clinical use. Drugs 1976;12:81-131.
3. Nomdedeu B, Ribera-Santasusana JM, Sanchez-Bisono J, Montserrat E, Rozman C. Megakaryocytic thrombocytopenic purpura caused by metoclopramide (letter). Sangre 1982;21(1):97-8.
4. Stevens GL, Adelman HM, Wallach PM. Palpable purpura: an algorithmic approach. Am Fam Physician 1995;52:1355-62.
5. Schreiner DT. Purpura. Dermatol Clin 1989;7:481-90.
6. Lightfoot RW. Palpable purpura: identifying the cause. Hosp Pract 1992; 27:39-47.
7. Dolan DL. Angiitis following procainamide therapy. Missouri Med 1968;65:365-6.
8. Knox JP, Welykyj SE, Gradini R, Massa MC. Procainamide-induced urticarial vasculitis. Cutis 1988;42:469-72.